Phase I and pharmacological study of oral 9-aminocamptothecin colloidal dispersion (NSC 603071) in patients with advanced solid tumors

Clinical Cancer Research

Volumn 9, Issue 6, 2003, Pages 2066-2071

  Xiong, Henry Q ^a   Tran, Hai T ^a   Madden, Timothy L ^a   Newman, Robert A ^a   Abbruzzese, James L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; ALKALINE PHOSPHATASE; BILIRUBIN; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE INHIBITOR; EXATECAN; IRINOTECAN; KARENITECIN; LACTONE; NSC 603071; TOPOTECAN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; COLLOID; CONSTIPATION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; SIDE EFFECT; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; VERTIGO; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS;

EID: 0037501242     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Zijlstra, J. G., DeJong, S., DeUries, E. G. E., and Mulder, N. H. Topoisomerases, new targets in cancer chemotherapy. Med. Oncol. Tumor Pharmacother., 7: 11-18, 1990.
2. Scheider, E., Hsiang, Y. H., and Liu, L. F. DNA topoisomerase as anticancer drug targets. Adv. Pharmacol., 21: 149-183, 1990.
3. Hsiang, Y., Lihou, M., and Liu, L. Arrest of the replication forks by the stabilized topoisomerase I-DNA cleavable complex as a mechanism of cell killing by camptothecin. Cancer Res., 49: 5077-5082, 1989.
4. Nitiss, J., and Wang, J. DNA-topoisomerase targeting antitumor drugs can be studied in yeast. Proc. Natl. Acad. Sci. USA, 85: 7501-7505, 1988.
5. Zhang, H., D'Arpa, P., and Liu, L. A model for cell killing by topoisomerase poisons. Cancer Cell, 2: 23-27, 1990.
6. Giovanella, B. C., Stehlin, J. S., Wall, M. E., et al. DNA topoisomerase I targeted chemotherapy of human colon cancer in xenografts. Science (Wash. DC), 246: 1046-1048, 1989.
7. Tanizawa, A., Fujimori, A., Fujimori, Y., and Pommier, Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J. Natl. Cancer Inst. (Bethesda), 86: 836-842, 1994.
8. Potmesil, M., Giovanella, B. C., Liu, L. F., et al. Preclinical studies of DNA topoisomerase I targeted 9-amino and 10, 11-methylenedioxy-camptothecin. In: M. Potmesil and K. W. Kohn (eds.), DNA Topoisomerases in Cancer, pp. 283-298. New York: Oxford University Press, 1991.
9. Potmesil, M., Giovanella, B. C., Wall, M. E., et al. Preclinical and clinical development of DNA-topoisomerase inhibitors in the United States. In: T. Andoh (ed.), The International Symposium on DNA Topoisomerases in Chemotherapy. New York: CRC Press, Inc., 1992.
10. Pantazis, P., Hinz, H. R., Mendoza, J. T., et al. Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res., 52: 3980-3987, 1992.
11. De Souza, P. L., Cooper, M. R., Imondi, A. R., et al. 9-aminocamptothecin: a topoisomerase I inhibitor with preclinical activity in prostate cancer. Clin. Cancer Res., 3: 287-294, 1997.
12. Eder, J. P., Supko, J. G., Lynch, T., et al. Phase I trial of the colloidal dispersion formulation of 9-amino-20 (S)-camptothecin administered as 72-hour continuous intravenous infusion. Clin. Cancer Res., 4: 317-324, 1998.
13. Vey, N., Kantarjian, H., Tran, H., et al. Phase I and Pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia. Ann. Oncol., 10: 577-583, 1999.
14. De Jonge, M. J. A., Punt, C. J. A., Gelderblom, A. H., et al. Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors. J. Clin. Oncol., 17: 2219-2226, 1999.
15. Leventhal, B. G., and Wittes, R. E. (eds.). Common Toxicity Criteria in Research Methods in Clinical Oncology. New York: Raven Press, 1988.
16. WHO. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: WHO Offset Publications, 1979.
17. Takimoto, C. H., Klecker, R. W., Dahut, W., et al. Analysis of the active lactone from 9-AC in plasma using solid-phase extraction and high-performance liquid cromatography. J. Chromatogr., 55: 97-104, 1994.
18. Giovanella, B., Hinz, H. R., Kozielsik, A. J., et al. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res., 51: 3052-3055, 1991.
19. Hertzberg, R. P., Caranfa, M. J., Holden, K. G., et al. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem., 32: 715-720, 1989.
20. Jaxel, C., Kohn, K. W., Wani, M. C., et al. Structure-activity study of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res., 49: 1465-1469, 1989.
21. Minami, H., Lad, T. E., Nicholas, M. K., et al. Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused 72 hours in phase II studies. Clin. Cancer Res., 5: 1325-1330, 1999.
22. Thomas, R. R., Dahut, W., and Harold, N. A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients. Cancer Chemother. Pharmacol., 48: 215-222, 2001.
23. Pazdur, R., Medgesy, D. C., Winn, R. J., et al. Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hour continuous infusion weekly for three weeks in metastatic colorectal carcinoma. Investig. New Drugs, 16: 341-346, 1999.
24. Pitot, H. C., Knost, J. A., Kugler, J., et al. A North Central Cancer Treatment Group phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma. Cancer (Phila.), 89: 1699-1705, 2000.
25. Mani, S., Iyer, L., Janisch, L., et al. Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). Cancer Chemother. Pharmacol., 42: 84-87, 1998.
26. Kirstein, M. N., Houghton, P. J., Richmond, L. B., et al. Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts. Clin. Cancer Res., 7: 358-366, 2001.